Korsana Biosciences Reports Third-Quarter 2026 EPS of ($3.19)
Korsana reported a wider third-quarter net loss as research and development and general and administrative expenses increased. Higher costs included stock-based compensation, spending on undisclosed programs, and personnel-related and chemistry, manufacturing and development costs.